Doxorubicin Hydrochloride Injection, Solution
Product Images NDC 25021-207

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 25021-207). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dox01 0013 01

Chemical structure diagram of doxorubicin hydrochloride, showing its complex molecular arrangement with multiple rings, hydroxyl groups, and an attached HCl molecule. The molecular formula (C27H29NO11•HCl) and molecular weight (579.99) are displayed.*

FDA Label Image

Dox01 0013 02

A forest plot chart displaying hazard ratios with 95% confidence intervals for six clinical trials comparing doxorubicin hydrochloride-based treatments to CMF (cyclophosphamide, methotrexate, fluorouracil). The trials are listed on the left, with their respective hazard ratio estimates plotted as squares with horizontal confidence interval bars. A diamond represents the combined doxorubicin-based study results at the bottom. The x-axis ranges from 0 to 2, indicating the spectrum from doxorubicin better than CMF to doxorubicin worse than CMF, with a vertical dashed line marking the boundary of non-inferiority.*

FDA Label Image

Dox01 0013 03

A forest plot comparing hazard ratios (with 95% confidence intervals) from six doxorubicin-based clinical trials versus CMF. The plot displays individual trial results as squares with horizontal confidence lines, and a combined effect represented by a diamond near the center line at hazard ratio 1.0, indicating no strong difference between doxorubicin-based and CMF treatments in this comparison.*

FDA Label Image

Dox01 0013 04

Label for doxorubicin hydrochloride Injection, USP, 50 mg per 25 mL (2 mg per mL) solution for intravenous use. The label indicates a 25 mL single-dose vial, cautions that it is a cytotoxic agent, and includes storage instructions. It is manufactured by Sagent Pharmaceuticals, Schaumburg, IL, and made in India. The label features warnings and dosage information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.